ASH 2023 | Financial and time toxicities in patients with multiple myeloma with active disease or in remission
Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, speaks on a survey conducted in patients with multiple myeloma (MM), which aimed to investigate the prevalence and predictors of both financial and time toxicity (FinTox and TimeTox, respectively), as well as the impact of these toxicities on quality of life (QoL) in this patient population. This is the most extensive study of these toxicities in multiple myeloma to date and provides valuable insight into the areas in which patients may require additional support. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: SparkCures, Janssen, BMS, Genentech, Sanofi, Caribou, Pfizer
Research Funding: Pack Health
